At a glance
ClinicalIndex Comparison RecordN/ACompleted· 114 enrolled
Drug / intervention
Moxonidine +1 moredrug
Likely dose
Moxonidine 0.4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS)
National Research Center for Preventive Medicine·interventional·Posted Feb 4, 2015·Updated Sep 1, 2021
In Brief
A clinical study evaluating Moxonidine and Bisoprolol for Osteopenia and Arterial Hypertension. Completed, enrolled 114 participants across 1 site.
Detailed Summary
This study evaluates the effect of moxonidine versus bisoprolol on collagen type 1 C-telopeptide in postmenopausal female patients with arterial hypertension and osteopenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteopenia, Arterial Hypertension
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartApr 2015
Primary CompletionJun 2018
Study CompletionJul 2018
TodayJul 2026
First PostedFeb 4, 2015
Enrollment StartApr 1, 2015
Primary CompletionJun 15, 2018
Study CompletionJul 10, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.4 years ago
Interventions
Moxonidinedrug
0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
Bisoprololdrug
5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D